MGI, the manufacturing subsidiary under BGI Corporation, has received China Food and Drug Administration (CFDA) certification for its latest two models of Next Generation genetic sequencers. MGISEQ-2000 and MGISEQ-200 sequencers have been granted the Medical Device Registration Certificate by CFDA on 25th June 2018, which makes BGI the first organisation in China to receive CFDA certification for Next Generation sequencing diagnostic products and medical devices. These sequencers will not just play an important role in scientific research, but also contribute to a wide range of applications in clinical medicine. Read the full media release here.
MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.